Veracyte Inc (VCYT)

Feb 21, 2025

Is Veracyte Stock a Good Addition to Your Portfolio Right Now? - Nasdaq

Feb 21, 2025

Feb 20, 2025

Veracyte (VCYT) Expected to Announce Quarterly Earnings on Monday - MarketBeat

Feb 20, 2025

Feb 20, 2025

8,074 Shares in Veracyte, Inc. (NASDAQ:VCYT) Acquired by Convergence Investment Partners LLC - MarketBeat

Feb 20, 2025

Feb 19, 2025

Veracyte to Participate in Upcoming Investor Conferences - WICZ

Feb 19, 2025

Feb 19, 2025

Can Veracyte's March Conference Circuit Signal Major Strategic Updates? - StockTitan

Feb 19, 2025

Feb 19, 2025

Rice Hall James & Associates LLC Decreases Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Feb 19, 2025

Feb 18, 2025

The Latest Breaking News from VCYT - Inkl

Feb 18, 2025

Feb 18, 2025

VCYT: 3 Emerging Biotech Firms Pioneering Next-Gen Therapies - StockNews.com

Feb 18, 2025

Feb 18, 2025

Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Feb 18, 2025

Feb 18, 2025

Veracyte (NASDAQ:VCYT) Cut to “Hold” at StockNews.com - Defense World

Feb 18, 2025

Feb 16, 2025

Veracyte Stock Soars to 52-Week High, Reaching $46.12 - MSN

Feb 16, 2025

Feb 15, 2025

Veracyte (NASDAQ:VCYT) Upgraded by StockNews.com to Buy Rating - MarketBeat

Feb 15, 2025

Feb 14, 2025

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - 01Net

Feb 14, 2025

Feb 12, 2025

Veracyte (NASDAQ:VCYT) Trading Down 7.1%What's Next? - MarketBeat

Feb 12, 2025

Feb 12, 2025

Sumitomo Mitsui Trust Group Inc. Sells 259,006 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Feb 12, 2025

Feb 11, 2025

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium - BioSpace

Feb 11, 2025

Feb 09, 2025

Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares - MarketBeat

Feb 09, 2025

Feb 08, 2025

Jennison Associates LLC Raises Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Feb 08, 2025

Feb 08, 2025

Blue Trust Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World

Feb 08, 2025

Feb 07, 2025

Veracyte CFO Rebecca Chambers sells $23,108 in stock - MSN

Feb 07, 2025

Feb 07, 2025

KBC Group NV Boosts Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - Defense World

Feb 07, 2025

Feb 07, 2025

Caprock Group LLC Sells 555 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World

Feb 07, 2025

Feb 06, 2025

Veracyte CFO Rebecca Chambers sells $23,108 in stock By Investing.com - Investing.com Australia

Feb 06, 2025

Feb 06, 2025

Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus.com

Feb 06, 2025

Feb 05, 2025

Veracyte CFO Sells Shares Under Pre-arranged Trading Plan - TradingView

Feb 05, 2025

Feb 05, 2025

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - BioSpace

Feb 05, 2025

Feb 04, 2025

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 - Business Wire

Feb 04, 2025

Feb 04, 2025

Veracyte (NASDAQ:VCYT) Sets New 52-Week High After Analyst Upgrade - MarketBeat

Feb 04, 2025

Feb 03, 2025

6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Baader Bank Aktiengesellschaft - MarketBeat

Feb 03, 2025

Feb 01, 2025

Veracyte (NASDAQ:VCYT) Rating Lowered to Hold at StockNews.com - MarketBeat

Feb 01, 2025

Feb 01, 2025

Needham & Company LLC Issues Positive Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat

Feb 01, 2025

Jan 31, 2025

Veracyte Stock Soars to 52-Week High, Reaching $46.12 By Investing.com - Investing.com Australia

Jan 31, 2025

Jan 31, 2025

Veracyte (NASDAQ:VCYT) Sets New 52-Week High on Analyst Upgrade - Defense World

Jan 31, 2025

Jan 30, 2025

Veracyte stock price target raised to $51 at Needham - MSN

Jan 30, 2025